Understanding DSCSA Requirements for Pharmacies

Millions of prescription drug transactions move through the supply chain every single day. Counterfeit medications, diverted products, and documentation gaps are real problems, not theoretical ones. The Drug Supply Chain Security Act was designed to address these risks. For pharmacies, this law isn’t background noise anymore—it’s an operational reality.

What Is DSCSA?

Passed in 2013 under Title II of the Drug Quality and Security Act, DSCSA established a framework for building an electronic, interoperable system to track prescription drugs across the entire supply chain. Manufacturers, wholesalers, repackagers, and dispensers all fall under its scope. Pharmacies included.

The law set a 10-year rollout timeline, with the heaviest requirements concentrated between 2023 and 2025. Operations that haven’t updated their workflows are carrying real exposure, both regulatory and practical. Getting a clear picture of the full DSCSA pharmacy requirements is a necessary step for any pharmacy that wants to stay on the right side of enforcement as it ramps up. The rules touch everything from how packages are labeled to how transaction records are stored and exchanged.

Core Requirements Pharmacies Must Meet

DSCSA compliance isn’t based on a single rule—it’s built on multiple core requirements working together. Understanding these is essential for maintaining safe and traceable pharmacy operations.

• Product Identification and Serialization

Every prescription drug package must carry a unique product identifier. This includes the National Drug Code, a serial number, a lot number, and an expiration date, all encoded in a 2D barcode. That much is fairly well known.

What’s less understood is the verification piece. For certain products, pharmacies are required to check that the serialized identifier at the point of dispensing, confirming the product is legitimate and that its history lines up with what was reported further up the chain.

• Transaction Data Requirements

When ownership of a drug product changes hands, DSCSA requires three documents to move with it: the Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS). Together, they create a traceable record that goes back to every previous sale.

Pharmacies need to both produce these records and receive them from trading partners. All of it must be retained for at least six years from the transaction date. That’s not a soft recommendation.

• Authorized Trading Partner Verification

Purchasing drugs from just any supplier isn’t permissible under DSCSA. Trading partners must be authorized, meaning they’re licensed manufacturers, repackagers, wholesale distributors, third-party logistics providers, or dispensers registered with the FDA.

Before completing a purchase, pharmacies should confirm their suppliers hold valid state and federal licenses. This step not only ensures compliance but also reduces the risk of receiving tampered or poorly documented products.

What the 2023 and 2025 Milestones Mean

The November 2023 milestone introduced enhanced drug distribution security requirements across the board. Pharmacies became responsible for exchanging standardized transaction data electronically and, in some cases, verifying product identifiers upon receipt.

The FDA has issued stabilization policies acknowledging that building out fully interoperable systems takes time. But don’t read that as an open invitation to stall. The FDA has been consistent about one thing: it expects real progress, and enforcement will reflect that.

By 2025, the end goal is a fully interoperable electronic system capable of real-time drug tracing. Getting there means investing in compatible software, updating receiving workflows, and making sure staff actually know what they’re doing with the new protocols.

Common Compliance Gaps

Most people overlook this part: the gaps that create the most risk aren’t usually the complicated ones. Poor record retention is a persistent problem. Many pharmacies still run manual processes that make retrieving transaction data under audit conditions difficult and slow.

Trading partner verification is another weak spot. Without a formal process for checking supplier licensure before each purchase cycle, it’s easy for a non-compliant transaction to slip through. One unauthorized purchase can generate serious legal exposure.

Receiving workflows round out the list. DSCSA requires pharmacies to investigate suspect or illegitimate products and report findings to the FDA. Without a clear procedure for flagging and quarantining questionable items, those obligations don’t get met.

Building a Sustainable Compliance Approach

Treating DSCSA as a one-time implementation project is a mistake. The requirements have already evolved significantly since 2013, and they’ll continue to shift. Pharmacies need systems that can move with them, not just systems that handled the last round of changes.

That means selecting pharmacy management software that supports electronic data exchange, running regular internal reviews to catch gaps before regulators do, and training staff consistently, not just at onboarding. Working with wholesale distribution partners who are already operating inside the DSCSA framework helps too. When traceability is shared infrastructure, compliance stops feeling like a solo effort.

The reality is that pharmacies treating DSCSA as an ongoing operational standard, rather than a box to check, are better positioned for audits, better aligned with trading partners, and better protected when something in the supply chain goes sideways. The investment pays off well beyond avoiding penalties.